Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus

Hemmingsen, Bianca; Sonne, David P.; Metzendorf, Maria‐Inti; Richter, Bernd

doi:10.1002/14651858.cd012151.pub2

Cited by 26 publications

(7 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of fixed dose of pioglitazone is better than multiple doses in improving glycemic control [13], [14]. Recommendation of the American Diabetes Association is that the metformin is the first line of treatment DM type 2 and decrease HbA1c [15].. Metformin reduces the risks of death and stroke more than insulin when comparing [16]. Metformin as a monotherapy leads to delay the glycemic control [17].…”

Section: Discussionmentioning

confidence: 99%

Contrasting Three Non-hypoglycemic Antidiabetic Drug Effects on Glycemic Control in Newly Diagnosed Type II Diabetes Mellitus: An Experimental Study

Hmood

Almasoody

Al-Jameel

2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Diabetes mellitus (DM) type 2 is the most public chronic, metabolic illness whose prevalence is quickly becoming high international. Insulin resistance, the essential metabolic problem leads to the development of DM type 2, is seen in about 90% of patients. AIM: The study’s aim was to compare the efficacy of three antidiabetic drugs on glycated hemoglobin. METHOD: A cross-sectional comparative study for newly diagnosed type II diabetic patients were assigned randomly into one of three conditions: Group I: Metformin consuming patients, Group II: Pioglitazone consuming patients, and Group III: Vildagliptin consuming patients. All patients were newly diagnosed. For all of them, baseline glycated hemoglobin was requested. After that, random assignment was carried out. After 3 months, glycated hemoglobin was checked and compared. RESULTS: Participants were distributed randomly into 27.9% metformin taking participants, 31.1% pioglitazone taking, and 41% vildagliptin taking patient. Findings suggested significant difference between Groups I and III (p =). Likewise, significant difference was seen between Groups II and III (p =). However, Groups I and II have comparable effects (p =). Indeed, all groups had shown significant efficacy on HbA1c. CONCLUSION: Metformin, pioglitazone, and vildagliptin had shown significant impact on HbA1c with variable degree: Metformin and pioglitazone had shown comparably similar efficacy that was exerted more significant impact on HbA1c than vildagliptin does.

show abstract

Section: Discussionmentioning

confidence: 99%

Contrasting Three Non-hypoglycemic Antidiabetic Drug Effects on Glycemic Control in Newly Diagnosed Type II Diabetes Mellitus: An Experimental Study

Hmood

Almasoody

Al-Jameel

2022

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…a combination of both (3) . A lower cut-off value for IFG (FPG 5.6-6.9 mmol/L) is employed by the American Diabetes Association.…”

Section: Abu Raghif Et Al (Nac) Administration In Prediabetic Patientsmentioning

confidence: 99%

Effects of N-Acetyl-Cysteine (Nac) Administration on Glucose Homeostasis Parameters in Prediabetic Patients

Raghif¹,

Yaseen²,

Dawood³

2018

IraqiJMS

View full text Add to dashboard Cite

Background: Prediabetes is determined on the bases of glycemic parameters, which are above normal but below diabetic thresholds. Prediabetes is associated with the presence of insulin resistance and β-cells dysfunction. N-acetyl cysteine (NAC), as a safe and inexpensive medication, is commercially accessible since long-time ago. This drug is not found in natural sources, although cysteine is present in some meals like chicken and turkey meats, garlic, yogurt, and eggs. NAC prevents apoptosis and oxygen related genotoxicity in endothelial cells by increasing intracellular levels of glutathione and decreasing mitochondrial membrane depolarization reaction. Objective: To evaluate the effects of NAC administration on glucose homeostasis parameters in prediabetic patients. Methods: This study included, 25 patients treated with dietary control and life style modifications for 12 weeks, 25 patients treated with NAC (600 mg) oral tablets twice daily plus dietary control and life style modifications for 12 weeks. Other 20 in addition to 50 patients to have an idea about the normal values of study parameters and in order to assess how much the drug used in the study were able to normalize the abnormal parameters. Results: NAC demonstrated a significant decrease in the fasting blood sugar, HbA1c, fasting Insulin and insulin resistance at the end of 12 weeks (P<0.05) compared with baseline measurements. Conclusion: The results of the study showed that N-acetyl cysteine has an effective effect on glycemic control. Keywords: Prediabetes , N-acetyl cysteine , glycemic control Citation: Abu Raghif AR, Yaseen YA, Dawood MH. Effects of N-Acetyl-Cysteine (NAC) administration on glucose homeostasis parameters in prediabetic patients. Iraqi JMS. 2018; 16(4): 393-399. doi: 10.22578/IJMS.16.4.6

show abstract

“…Changes in lifestyle, such as daily physical activity and a healthy diet, can reduce the risk of prediabetes, improve the health of diabetic patients, and prevent complications [ 7 ]. Consultations with health care professionals at medical facilities are commonly used to modify a person’s lifestyle.…”

Section: Introductionmentioning

confidence: 99%

The Use of Mobile Health Interventions for Outcomes among Middle-Aged and Elderly Patients with Prediabetes: A Systematic Review

Jeem

Andriani

Nabila

et al. 2022

IJERPH

View full text Add to dashboard Cite

Background: There are currently limited systematic reviews of mobile health interventions for middle-aged and elderly patients with prediabetes from trial studies. This review aimed to gather and analyze information from experimental studies investigating the efficacy of mobile health usability for outcomes among middle-aged and elderly patients with prediabetes. Methods: We conducted a literature search in five databases: Clinicaltrials.gov, the International Clinical Trials Registry Platform (ICTRP), PubMed, ProQuest, and EBSCO, with a date range of January 2007 to July 2022 written in English, following a registered protocol on PROSPERO (CRD42022354351). The quality and possibility of bias were assessed using the Jadad score. The data extraction and analysis were conducted in a methodical manner. Results: A total of 25 studies were included in the qualitative synthesis, with 19 studies using randomized trial designs and 6 studies with non-randomized designs. The study outcomes were the incidence of diabetes mellitus, anthropometric measures, laboratory examinations, measures of physical activity, and dietary behavior. During long-term follow-up, there was no significant difference between mobile health interventions and controls in reducing the incidence of type 2 diabetes. The findings of the studies for weight change, ≥3% and ≥5% weight loss, body mass index, and waist circumference changes were inconsistent. The efficacy of mobile health as an intervention for physical activity and dietary changes was lacking in conclusion. Most studies found that mobile health lacks sufficient evidence to change hbA1c. According to most of these studies, there was no significant difference in blood lipid level reduction. Conclusion: The use of mobile health was not sufficiently proven to be effective for middle-aged and elderly patients with prediabetes.

show abstract

Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus

Abstract: There is insufficient evidence to demonstrate whether insulin secretagogues compared mainly with placebo reduce the risk of developing T2DM and its associated complications in people at increased risk for the development of T2DM. Most trials did not investigate patient-important outcomes.

Cited by 26 publications

References 100 publications

Contrasting Three Non-hypoglycemic Antidiabetic Drug Effects on Glycemic Control in Newly Diagnosed Type II Diabetes Mellitus: An Experimental Study

Contrasting Three Non-hypoglycemic Antidiabetic Drug Effects on Glycemic Control in Newly Diagnosed Type II Diabetes Mellitus: An Experimental Study

Effects of N-Acetyl-Cysteine (Nac) Administration on Glucose Homeostasis Parameters in Prediabetic Patients

The Use of Mobile Health Interventions for Outcomes among Middle-Aged and Elderly Patients with Prediabetes: A Systematic Review

Contact Info

Product

Resources

About